Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

BACKGROUND: New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. METHODS: We conducted a phase 1 do...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Roberts, Andrew W., Davids, Matthew S., Pagel, John M., Kahl, Brad S., Puvvada, Soham D., Gerecitano, John F., Kipps, Thomas J., Anderson, Mary Ann, Brown, Jennifer R., Gressick, Lori, Wong, Shekman, Dunbar, Martin, Zhu, Ming, Desai, Monali B., Cerri, Elisa, Enschede, Sari Heitner, Humerickhouse, Rod A., Wierda, William G., Seymour, John F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7107002/
https://ncbi.nlm.nih.gov/pubmed/26639348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1513257
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados